Anti-leishmanial Nanotherapeutics: A Current Perspective.

Area of Science:

• Parasitology
• Nanotechnology
• Pharmacology

Background:

• Leishmaniasis is a severe global disease caused by Leishmania parasites, leading to significant illness and death.
• Current chemotherapy for leishmaniasis faces challenges including toxicity, poor bioavailability, high costs, and drug resistance.
• The development of novel anti-leishmanial nanotherapeutics presents a potential strategy to overcome these limitations.

Purpose of the Study:

• To review the application of nanotechnology in developing anti-leishmanial therapeutics.
• To explore the potential of nanotherapeutics in improving drug and vaccine delivery for leishmaniasis.

Main Methods:

• Extensive literature search of bibliographic databases for peer-reviewed articles.
• Focus on research concerning nanotechnology in drug development, drug delivery, and vaccine delivery for anti-leishmanial applications.

Main Results:

• Nanotechnology demonstrates significant potential in anti-leishmanial therapeutics.
• Nanotechnology facilitates targeted drug delivery, enhancing bioavailability and reducing toxicity.
• Application of nanotechnology can help address chemoresistance in leishmaniasis treatment.

Conclusions:

• Anti-leishmanial nanotherapeutics show promise for effective treatment of leishmaniasis.
• While direct nanoparticle use as therapeutics is limited, nanotechnology applications in vaccine development are emerging.
• Nano-based drug delivery systems for leishmaniasis have advanced, holding potential to transform treatment paradigms.